J. Aluri

发表

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants

R. Shumaker, J. Aluri, Jean Fan, 2014, Clinical pharmacology in drug development.

Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention

N. Kleiman, J. Aluri, D. Cox, 2004, Journal of clinical pharmacology.

First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing

A. Satlin, B. Albala, R. Lai, 2012, Alzheimer's & Dementia.

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

M. Moline, J. Aluri, G. Filippov, 2021, Pharmacology research & perspectives.

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

M. Moline, J. Aluri, G. Filippov, 2021, Pharmacology research & perspectives.

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study

B. Setnik, M. Moline, J. Aluri, 2022, Journal of psychopharmacology.

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects

J. Ferry, J. Aluri, Maiko Nomoto, 2018, Clinical pharmacology in drug development.

Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study

P. Boyd, J. Aluri, L. Y. Ngo, 2022, Clinical pharmacology in drug development.

Disposition and Metabolism of [14C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites

T. Ishida, S. Asakura, C. Beuckmann, 2020, Drug Metabolism and Disposition.

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

J. Ferry, E. Schuck, P. Boyd, 2018, British journal of clinical pharmacology.

Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females

M. Moline, J. Aluri, G. Filippov, 2021, Clinical pharmacology in drug development.

An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors

R. Shumaker, J. Aluri, M. Ren, 2020, European Journal of Drug Metabolism and Pharmacokinetics.

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers

J. Aluri, S. Hojo, Y. Kitahara, 2022, Clinical pharmacology in drug development.

Influence of hepatic impairment on lenvatinib pharmacokinetics following single‐dose oral administration

R. Shumaker, J. Aluri, Jean Fan, 2015, Journal of clinical pharmacology.

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

J. Henningfield, B. Setnik, M. Moline, 2022, Journal of clinical psychopharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults

J. Ferry, M. Moline, J. Aluri, 2020, Clinical pharmacology in drug development.

Subcutaneous Dose Selection of Lecanemab for Treatment of Subjects with Early Alzheimer’s Disease (EAD)

P. Boyd, J. Aluri, B. Willis, 2022, Alzheimer's & Dementia.

ELENBECESTAT PHARMACOKINETIC DRUG-DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS

J. Ferry, B. Albala, R. Lai, 2017, Alzheimer's & Dementia.

A population pharmacokinetic‐pharmacodynamic and logistic regression analysis of lotrafiban in patients

D. Mould, J. Granett, J. Aluri, 2001, Clinical pharmacology and therapeutics.

Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant

Borje Darpo, Takashi Yoshinaga, Nancy Hall, 2017, Journal of clinical pharmacology.

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder

M. Moline, J. Aluri, O. Majid, 2020, Journal of clinical pharmacology.

Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults

R. Shumaker, J. Aluri, Jean Fan, 2014, Clinical Drug Investigation.

Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.

R. Shumaker, J. Aluri, Jean Fan, 2014, International journal of clinical pharmacology and therapeutics.

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant

M. Moline, J. Aluri, G. Filippov, 2021, Clinical pharmacology in drug development.

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027

E. Schuck, P. Boyd, J. Aluri, 2022, Alzheimer disease and associated disorders.

E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies

B. Darpo, J. Aluri, Hongqi Xue, 2022, Alzheimer disease and associated disorders.

Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers

J. Aluri, Linda Manning, Vaishali Pade, 1995, Biopharmaceutics & drug disposition.

Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers

B. Darpo, R. Shumaker, J. Aluri, 2014, Cancer Chemotherapy and Pharmacology.

Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist

R. Lai, S. Ishizaka, M. Matijević, 2018 .

CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609

A. Satlin, M. Matijević, J. Aluri, 2012, Alzheimer's & Dementia.

Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)

J. Aluri, O. Majid, Taro Hihara, 2024, CPT: pharmacometrics & systems pharmacology.

Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects.

P. Boyd, J. Aluri, F. Bibbiani, 2011, Clinical therapeutics.